Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)

John S. Macdonald, Jacqueline K. Benedetti, Manuel Modiano, David S. Alberts

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

The topoisomerase-1 inhibitor, topotecan, was tested in 48 eligible patients with advanced colorectal cancer. The patients had no prior chemotherapy and a Southwest Oncology Group performance status of 0-2. Topotecan was administered intravenously at 1.5 mg/m2/day for five days and repeated every 21 days. The major toxicity was hematologic with 19 out of 48 (40%) patients having grade IV granulocytopenia and 4 out of 48 (8%) patients demonstrating grade IV thrombocytopenia. Two patients (4%) demonstrated partial response. Thirty patients have died and the Kaplan-Meier estimate of median survival is 9 months (95% confidence interval, 7-16 months). Topotecan in this dose and schedule does not appear active in patients with advanced colorectal cancer.

Original languageEnglish (US)
Pages (from-to)357-359
Number of pages3
JournalInvestigational New Drugs
Volume15
Issue number4
DOIs
StatePublished - Dec 1 1997
Externally publishedYes

Keywords

  • Colorectal cancer
  • Topoisomerase-1 inhibitor
  • Topotecan

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II evaluation of topotecan in patients with advanced colorectal cancer. A Southwest Oncology Group trial (SWOG 9241)'. Together they form a unique fingerprint.

  • Cite this